Search - tctmd.com

Displaying 1 - 20 of 149

Sort: Relevancy | Date

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

Aspirin Use for Primary Prevention Declining in US: NHANES

Michael O'Riordan

January 24, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News VIVA 2024

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

L.A. McKeown

November 14, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

AHA Celebrates a Century by Looking Back, and Forward

Shelley Wood

June 10, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

Todd Neale

March 15, 2024

News Daily News

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Todd Neale

February 14, 2024

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

Advertisement

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Aspirin Use for Primary Prevention Declining in US: NHANES

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

AHA Celebrates a Century by Looking Back, and Forward

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content